Research programme: stroke therapies - AGY Therapeutics
Latest Information Update: 10 Oct 2006
At a glance
- Originator AGY Therapeutics
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Stroke
Most Recent Events
- 10 Oct 2006 Discontinued - Preclinical for Stroke in USA (PO)
- 02 Sep 2002 Preclinical trials in stroke in USA (PO)